Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat
COPENHAGEN, February 7, 2026, 23:19 CET — The market is closed. Novo Nordisk A/S Class B shares could see renewed attention Monday, after Hims & Hers said it's pulling the $49 compounded Wegovy pill, responding to U.S. regulators. Novo’s Copenhagen-listed stock closed out Friday at 295.50 crowns, climbing 5.3%, Reuters data showed.